Private Trust Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.55M Sell
37,952
-563
-1% -$121K 0.76% 15
2026
Q1
$8.38M Sell
38,515
-378
-1% -$83.8K 0.75% 15
2025
Q4
$8.89M Sell
38,893
-111
-0.3% -$25.3K 0.78% 15
2025
Q3
$9.03M Buy
39,004
+1,239
+3% +$252K 0.8% 14
2025
Q2
$7.01M Buy
37,765
+779
+2% +$145K 0.67% 18
2025
Q1
$7.75M Buy
36,986
+602
+2% +$117K 0.8% 15
2024
Q4
$6.47M Buy
36,384
+662
+2% +$122K 0.66% 20
2024
Q3
$7.05M Buy
35,722
+559
+2% +$104K 0.71% 18
2024
Q2
$6.03M Sell
35,163
-2,708
-7% -$449K 0.65% 24
2024
Q1
$6.9M Buy
37,871
+215
+0.6% +$37.1K 0.74% 19
2023
Q4
$5.84M Sell
37,656
-1,558
-4% -$227K 0.69% 22
2023
Q3
$5.85M Sell
39,214
-199
-0.5% -$29.2K 0.77% 20
2023
Q2
$5.31M Sell
39,413
-1,586
-4% -$233K 0.67% 24
2023
Q1
$6.53M Buy
40,999
+2,893
+8% +$442K 0.89% 12
2022
Q4
$6.16M Sell
38,106
-1,466
-4% -$225K 0.91% 14
2022
Q3
$5.31M Buy
39,572
+2,783
+8% +$399K 0.86% 16
2022
Q2
$5.63M Sell
36,789
-6,126
-14% -$936K 0.88% 14
2022
Q1
$6.96M Buy
42,915
+1,564
+4% +$227K 1.09% 14
2021
Q4
$5.6M Buy
41,351
+1,141
+3% +$135K 0.77% 25
2021
Q3
$4.34M Buy
40,210
+2,030
+5% +$232K 0.63% 34
2021
Q2
$4.3M Buy
38,180
+81
+0.2% +$9.12K 0.65% 31
2021
Q1
$4.12M Sell
38,099
-592
-2% -$63.3K 0.67% 29
2020
Q4
$4.14M Sell
38,691
-2,308
-6% -$222K 0.7% 29
2020
Q3
$3.59M Sell
40,999
-1,276
-3% -$120K 0.69% 29
2020
Q2
$4.18M Buy
42,275
+2,349
+6% +$207K 0.88% 16
2020
Q1
$3.04M Sell
39,926
-16,026
-29% -$1.37M 0.79% 27
2019
Q4
$4.95M Buy
55,952
+1,831
+3% +$152K 0.92% 18
2019
Q3
$4.1M Buy
54,121
+4,451
+9% +$305K 0.81% 23
2019
Q2
$3.61M Sell
49,670
-1,347
-3% -$106K 0.73% 29
2019
Q1
$4.11M Sell
51,017
-973
-2% -$79.6K 0.86% 20
2018
Q4
$4.79M Sell
51,990
-7,898
-13% -$695K 1.14% 13
2018
Q3
$5.66M Sell
59,888
-1,275
-2% -$121K 1.16% 12
2018
Q2
$5.67M Sell
61,163
-1,077
-2% -$105K 1.23% 11
2018
Q1
$5.89M Sell
62,240
-1,794
-3% -$197K 1.29% 11
2017
Q4
$6.19M Sell
64,034
-13,027
-17% -$1.23M 1.31% 10
2017
Q3
$6.85M Sell
77,061
-9,479
-11% -$722K 1.49% 9
2017
Q2
$6.27M Buy
86,540
+5,219
+6% +$351K 1.37% 11
2017
Q1
$5.3M Sell
81,321
-525
-0.6% -$33K 1.22% 14
2016
Q4
$5.13M Sell
81,846
-3,839
-4% -$234K 1.23% 15
2016
Q3
$5.4M Sell
85,685
-5,348
-6% -$346K 1.32% 12
2016
Q2
$5.63M Buy
91,033
+3,704
+4% +$226K 1.47% 9
2016
Q1
$4.99M Buy
87,329
+3,938
+5% +$219K 1.35% 12
2015
Q4
$4.94M Sell
83,391
-9,186
-10% -$529K 1.41% 11
2015
Q3
$5.04M Buy
92,577
+12,534
+16% +$816K 1.51% 10
2015
Q2
$5.38M Buy
80,043
+858
+1% +$56K 1.54% 6
2015
Q1
$4.63M Buy
79,185
+12,367
+19% +$747K 1.33% 12
2014
Q4
$4.37M Buy
66,818
+6,446
+11% +$406K 1.39% 12
2014
Q3
$3.49M Buy
60,372
+29,706
+97% +$1.65M 1.18% 12
2014
Q2
$1.73M Buy
30,666
+2,820
+10% +$148K 0.56% 39
2014
Q1
$1.43M Sell
27,846
-10,491
-27% -$530K 0.54% 41
2013
Q4
$2.02M Buy
38,337
+1,709
+5% +$84K 0.81% 26
2013
Q3
$1.64M Sell
36,628
-964
-3% -$42.7K 0.74% 32
2013
Q2
$1.55M Buy
+37,592
New +$1.64M 0.71% 33

Other funds holding ABBV

Private Trust Company's ABBV Position: Q2 2026 in Review

Private Trust Company reduced its AbbVie (ABBV) stake by 1.5% in Q2 2026, selling an estimated $121K and leaving 37,952 shares worth $9.55M. The position accounts for 0.76% of the portfolio, ranked #15.

Private Trust Company first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Private Trust Company held 37,952 shares of AbbVie worth $9.55M as of Q2 2026.
  • Private Trust Company sold 563 AbbVie shares in Q2 2026, an estimated $121K.
  • AbbVie made up 0.76% of Private Trust Company's portfolio in Q2 2026, its #15 holding.
  • Private Trust Company first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.